Market Research Logo

Malignant Melanoma: Update Bulletin [Jan 2016]

Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.

Introduction

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy’s (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA’s approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma’s binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen’s newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.

Reasons to Purchase

Key Questions Answered in this Update Bulletin:

Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?

To what extent will Keytruda be used as a first-line therapy for advanced melanoma?

Will Opdivo plus Yervoy’s superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?

What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?

How significantly will the need for patient monitoring impact Yervoy’s uptake in stage III melanoma?

How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Introduction

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo’s (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy’s (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA’s approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma’s binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen’s newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.

Reasons to Purchase

Key Questions Answered in this Update Bulletin:

Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?

To what extent will Keytruda be used as a first-line therapy for advanced melanoma?

Will Opdivo plus Yervoy’s superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?

What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?

How significantly will the need for patient monitoring impact Yervoy’s uptake in stage III melanoma?

How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;